Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2452 | Placebo (NaCl 0.9%) (Group 2D) Wiki | 1.00 |
drug2862 | SARS-CoV-2 IgG Antibody Testing Kit Wiki | 0.71 |
drug2863 | SARS-CoV-2 PCR Wiki | 0.50 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.05 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There are 2 clinical trials
A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals
Description: Primary target variables are (S)AEs and Adverse Events of Special Interest (AESIs)
Measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Time: 3 MonthDescription: Reactogenicity Events occurring during the first week after study drug administration will be separately summarized based on their relationship to the study drug.
Measure: Incidence of Reactogenicity Adverse Events [Safety and Tolerability] Time: 1. WeekDescription: AUC0-672 (the area under the concentration-time curve of DZIF-10c in serum over the time interval from 0 to 672 hours (Day 28))
Measure: Pharmacokinetic parameter AUC0-672 Time: 0 to 672 hoursDescription: AUC0-504 (the area under the concentration-time curve of DZIF-10c in serum over the time interval from 0 to 504 hours) in healthy volunteers
Measure: Pharmacokinetic parameter tmax Time: 0 to 504 hoursDescription: AUC0-inf (the area under the concentration-time curve of DZIF-10c in serum over the time interval from 0 extrapolated to infinity)
Measure: Pharmacokinetic parameter AUC0-inf Time: 3 MonthDescription: Cmax (maximum measured concentration of DZIF-10c in serum)
Measure: Pharmacokinetic parameter Cmax Time: 3 MonthDescription: t1/2 (the terminal elimination half-life of DZIF-10c in serum)
Measure: Pharmacokinetic parameter t1/2 Time: 3 MonthDescription: CL (total clearance of DZIF-10c in serum following i.v. administration)
Measure: Pharmacokinetic parameter CL Time: 3 MonthDescription: Vss (volume of distribution at steady state following i.v. administration)
Measure: Pharmacokinetic parameter Vss Time: 3 MonthDescription: Vz (volume of distribution during the terminal phase following i.v. administration)
Measure: Pharmacokinetic parameter Vz Time: 3 MonthDescription: The frequency of participants with antibodies and magnitude of antibodies targeting DZIF-10c will be calculated and described in tables.
Measure: Anti-Drug Antibodies Time: 3 MonthDescription: Viral Shedding Determined by qRT-PCR in nasopharyngeal swabs
Measure: Viral Shedding nasopharyngeal Time: Day 0-28Description: Viral Shedding Determined by qRT-PCR in oropharyngeal swabs
Measure: Viral Shedding oropharyngeal Time: Day 0-28Description: Frequency of viral shedding by as determined by successful isolation of infectious virus in virus isolation assays will be analysed by visit at baseline and at days 1 and 3 (Groups 2C-2D).
Measure: Viral Shedding Determined by the Isolation of Infectious Virus Time: Day 0-3Description: Levels of subgenomic SARS-CoV-2 mRNA will be determined swab samples by qRT-PCR (Groups 2C-2D).
Measure: Viral Replication Determined by Subgenomic SARS-CoV-2 mRNA Time: 3 MonthDescription: The frequency of unplanned hospitalizations and medically-attended contacts deemed to be related to COVID-19 by the Investigator will be described (Groups 2C-2D).
Measure: Frequency of COVID-19-related hospitalizations and medically-attended contacts Time: 3 MonthDescription: The duration of COVID-19-related symptoms will be described based on participants's self-assessment documented on patient diaries.
Measure: Duration of COVID-19 symptoms Time: 3 MonthDescription: SARS-CoV-2-reactive B cells and T cells are evaluated as number of participants with reactive cells and as activity of reactive cells. This analysis only takes place in SARS-CoV-2-infected individuals (2C, 2D).
Measure: Activity and Frequency of SARS-CoV-2-reactive immune responses Time: 3 MonthA Phase 1/2a Trial of the Inhaled Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected individuals
Description: Primary target variables are (S)AEs and Adverse Events of Special Interest (AESIs)
Measure: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Time: 3 MonthDescription: Reactogenicity Events occurring during the first week after study drug administration will be separately summarized based on their relationship to the study drug.
Measure: Incidence of Reactogenicity Adverse Events [Safety and Tolerability] Time: 1. WeekDescription: AUC0-672 (the area under the concentration-time curve of DZIF-10c in serum over the time interval from 0 to 672 hours (Day 28))
Measure: Pharmacokinetic parameter AUC0-672 Time: 0 to 672 hoursDescription: AUC0-504 (the area under the concentration-time curve of DZIF-10c in serum over the time interval from 0 to 504 hours) in healthy volunteers
Measure: Pharmacokinetic parameter tmax Time: 0 to 504 hoursDescription: AUC0-504 (the area under the concentration-time curve of DZIF-10c in serum over the time interval from 0 to 504 hours) in healthy volunteers
Measure: Pharmacokinetic parameter AUC0-inf Time: 0 to 504 hoursDescription: Cmax (maximum measured concentration of DZIF-10c in serum)
Measure: Pharmacokinetic parameter Cmax Time: 3 MonthDescription: t1/2 (the terminal elimination half-life of DZIF-10c in serum)
Measure: Pharmacokinetic parameter t1/2 Time: 3 MonthDescription: CL (total clearance of DZIF-10c in serum following i.v. administration)
Measure: Pharmacokinetic parameter CL Time: 3 MonthDescription: Vss (volume of distribution at steady state following i.v. administration)
Measure: Pharmacokinetic parameter Vss Time: 3 MonthDescription: Vz (volume of distribution during the terminal phase following i.v. administration)
Measure: Pharmacokinetic parameter Vz Time: 3 MonthDescription: The frequency of participants with antibodies and magnitude of antibodies targeting DZIF-10c will be calculated and described in tables.
Measure: Anti-Drug Antibodies Time: 3 MonthDescription: Viral Shedding Determined by qRT-PCR in nasopharyngeal swabs
Measure: Viral Shedding nasopharyngeal Time: Day 0-28Description: Viral Shedding Determined by qRT-PCR in oropharyngeal swabs
Measure: Viral Shedding oropharyngeal Time: Day 0-28Description: Frequency of viral shedding by as determined by successful isolation of infectious virus in virus isolation assays will be analysed by visit at baseline and at days 1 and 3 (Groups 2C-2D).
Measure: Viral Shedding Determined by the Isolation of Infectious Virus Time: Day 0-3Description: Levels of subgenomic SARS-CoV-2 mRNA will be determined swab samples by qRT-PCR (Groups 2C-2D).
Measure: Viral Replication Determined by Subgenomic SARS-CoV-2 mRNA Time: 3 MonthDescription: The frequency of unplanned hospitalizations and medically-attended contacts deemed to be related to COVID-19 by the Investigator will be described (Groups 2C-2D).
Measure: Frequency of COVID-19-related hospitalizations and medically-attended contacts Time: 3 MonthDescription: The duration of COVID-19-related symptoms will be described based on participants's self-assessment documented on patient diaries.
Measure: Duration of COVID-19 symptoms Time: 3 MonthDescription: SARS-CoV-2-reactive B cells and T cells are evaluated as number of participants with reactive cells and as activity of reactive cells. This analysis only takes place in SARS-CoV-2-infected individuals (2C, 2D).
Measure: Activity and Frequency of SARS-CoV-2-reactive immune responses Time: 3 MonthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports